Drug Trial Radar · NCT00459446
Imaging of Totally Blocked Arteries
Last checked: Nov 20, 2026Latest source record: Jul 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Apr 5, 2007
Primary completion
Nov 25, 2008
Sponsor
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)NIH
- Sponsor type
- NIH
- First posted
- Apr 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test how well a new contrast agent (dye) used in magnetic resonance imaging (MRI) can help visualize totally blocked arteries that normally supply blood to the neck, arms or legs. Currently used agents work well in visualizing normal or partly blocked arteries (arteries that have some blood flowing through them), but only poorly in totally blocked arteries. This study will see if a contrast agent called gadofosveset can better brighten images of completely blocked arteries. Gadofosveset is approved in Europe for use in MRI scans, but is still considered experimental in the United States. People 18 years of age or older with known or suspected total blockage of an artery to the neck, arm or leg may be eligible for this study. Participants undergo MRI scanning with gadofosveset contrast dye. MRI uses a magnetic field and radio waves to produce images of body tissues and organs. For this procedure, the subject lies on a table that can slide in and out of the tubular scanner, wearing earplugs to muffle loud noises that occur during the scanning process. The procedure lasts about 1.5 to 2 hours, during which the subject may be asked to hold his or her breath several times for as long as 5 to 20 seconds. During the procedure, gadofosveset is injected and several kinds of MRI pictures are taken to understand better how the new agent works. Subjects may be asked to undergo a second scan using conventional MRI contrast dye
Conditions
- Atherosclerosis
- Peripheral Artery Disease
- Intermittent Claudication
- Chronic Total Aterial Occlusion
Interventions
MS-325 Injection (Gadofosveset Trisodium)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Conspicuity of occluded arteries after contrast exposure.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.